Controlled Trial of Angiotensin Receptor Blocker (ARB) & Chemokine Receptor Type 2 (CCR2) Antagonist for the Treatment of COVID-19

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
CLARITY 2.0 is an investigator-initiated trial that will evaluate the safety and efficacy of dual treatment with repagermanium, a CCR2 antagonist, and candesartan, an ARB, in patients hospitalised with COVID-19 disease.
Epistemonikos ID: 4e5f6d0b493c346b5d68a3a5799250627108532e
First added on: Nov 17, 2021